E. M. Dmitrieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. M. Dmitrieva has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry O. Ivanov
Санкт-Петербургский государственный педиатрический медицинский университет
1 shared publication - E. A. Efet
Saint Petersburg Pediatric Medical University
1 shared publication - E. A. Pankov
Saint-Petersburg State Pediatric Medical University
1 shared publication - Elena A. Kornienko
St. Petersburg State Pediatric Medical University
1 shared publication - Elena P. Fedotova
Saint Petersburg State Pediatric Medical University
1 shared publication - Elizaveta Y. Makarova
Department of Hospital Pediatrics, Saint Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg 194100, Russia
1 shared publication
Latest Publications
- Open Access
- 8 March 2023
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (1) , 92-101
The use of the drug Elizaria – a biosimilar of the original eculizumab in atypical hemolytic-uremic syndrome due to mutation of the С3 gene in children: clinical observation and literature review
This article presents the features of atypical haemolytic-uremic syndrome (ORPHA 544472) in children. Atypical haemolytic-uremic syndrome (aHUS) is defined by a triad: haemolytic anaemia, thrombocytopenia and acute kidney injury in pediatric and adult patients. The OMIM catalogue presents the phenotypic series of aHUS with mutations of the C3, CFB, CFH, CFHR1, CFHR3, DGKE, MCP, THBD genes. Atypical haemolytic-uremic syndrome is often associated with gene mutations in proteins and activators that regulate complement. We report the case of a girl who had a manifestation of aHUS at 8 years 5 months of age and a severe relapse at 8 years 10 months of age. The relapse was characterised by manifestations of haemolytic anaemia, thrombocytopenia, acute renal damage, severe arterial hypertension, high lactate dehydrogenase and membrane attack complex levels and low C3 component. After 5 courses of haemodialysis, 3 haemodiafiltration, diuresis increased and biochemical parameters improved. We presented with ASUS in a child associated with a p.Cys1101Tyr C3 gene mutation. We used a complement inhibitor, Elizaria®, a biosimilar to the original drug eculizumab, to treat a child with atypical haemolytic-uremic syndrome due to the C3 gene mutation. The complement system inhibitor therapy with Elizaria preserved the health and life of a sick girl with a severe relapse of aHUS.
- 8 March 2023
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (1) , 92-101
Open AccessThe use of the drug Elizaria – a biosimilar of the original eculizumab in atypical hemolytic-uremic syndrome due to mutation of the С3 gene in children: clinical observation and literature review
This article presents the features of atypical haemolytic-uremic syndrome (ORPHA 544472) in children. Atypical haemolytic-uremic syndrome (aHUS) is defined by a triad: haemolytic anaemia, thrombocytopenia and acute kidney injury in pediatric and adult patients. The OMIM catalogue presents the phenotypic series of aHUS with mutations of the C3, CFB, CFH, CFHR1, CFHR3, DGKE, MCP, THBD genes. Atypical haemolytic-uremic syndrome is often associated with gene mutations in proteins and activators that regulate complement. We report the case of a girl who had a manifestation of aHUS at 8 years 5 months of age and a severe relapse at 8 years 10 months of age. The relapse was characterised by manifestations of haemolytic anaemia, thrombocytopenia, acute renal damage, severe arterial hypertension, high lactate dehydrogenase and membrane attack complex levels and low C3 component. After 5 courses of haemodialysis, 3 haemodiafiltration, diuresis increased and biochemical parameters improved. We presented with ASUS in a child associated with a p.Cys1101Tyr C3 gene mutation. We used a complement inhibitor, Elizaria®, a biosimilar to the original drug eculizumab, to treat a child with atypical haemolytic-uremic syndrome due to the C3 gene mutation. The complement system inhibitor therapy with Elizaria preserved the health and life of a sick girl with a severe relapse of aHUS.
- 16 December 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (6)
CLINICAL CASE OF MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY
A clinical case of mitochondrial neurogastrointestinal encephalopathy (MNGIE), a rare autosomal recessive multisystem disease caused by TYMP gene mutations and thymidine phosphorylase (TP) deficiency, is presented. Authors draw the specialists’ attention to the complexity of making a diagnosis and the importance of an interdisciplinary approach in the diagnosis and management of such patients with the purpose of increasing the pediatric practitioners’ MNGIE awareness thereby reducing the time to diagnosis, which in its turn improves the prognosis for the course of the disease for the patients.
- 16 December 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (6)
CLINICAL CASE OF MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY
A clinical case of mitochondrial neurogastrointestinal encephalopathy (MNGIE), a rare autosomal recessive multisystem disease caused by TYMP gene mutations and thymidine phosphorylase (TP) deficiency, is presented. Authors draw the specialists’ attention to the complexity of making a diagnosis and the importance of an interdisciplinary approach in the diagnosis and management of such patients with the purpose of increasing the pediatric practitioners’ MNGIE awareness thereby reducing the time to diagnosis, which in its turn improves the prognosis for the course of the disease for the patients.